Evidence map›Paper›PMID 40152495›Full record

ArticleThe British journal of dermatology2025

The landscape of long noncoding RNA during cutaneous squamous cell carcinoma progression.

Max Bone, Daniel Schreyer, Mairi Treanor-Taylor, Charlotte M Proby, Catherine A Harwood, Irene M Leigh, Peter Bailey, Gareth J Inman

Abstract read
In one paragraph

Article in The British journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Max BoneSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0001-8589-3343
Daniel SchreyerSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-9788-0168
Mairi Treanor-TaylorSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-8908-3900
Charlotte M ProbyMolecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK.ORCID 0000-0002-3292-4836
Catherine A HarwoodCentre for Cell Biology and Cutaneous Research, Blizzard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0002-1375-0965
Irene M LeighCentre for Cell Biology and Cutaneous Research, Blizzard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0001-8536-6439
Peter BaileySchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-0857-2041
Gareth J InmanSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-6264-4253

Funding

British Skin Foundation 004_S_19Cancer Research UKCRUK Scotland Institute A31287
6 · The paper itself

Abstract

backgroundCutaneous squamous cell carcinoma (cSCC) is a common cancer with a high morbidity rate and poor prognosis for metastatic disease. Disease may progress from premalignant actinic keratosis to invasive and metastatic cSCC, but it is perhaps best characterized as a disease continuum progressing from a differentiated to a progenitor-like state. The critical molecular mediators of this process remain poorly defined. Long noncoding (lnc)RNAs, a relatively unexplored class of RNA molecules > 200 nucleotides long, are likely to have important functional roles in cSCC.

objectivesTo provide a comprehensive landscape of lncRNA expression during the cSCC continuum and to identify potentially functional lncRNA drivers of disease progression.

methodsWe interrogated bulk RNA sequencing (RNAseq) data from 110 patient samples, encompassing healthy sun-exposed skin (n = 26), actinic keratosis (n = 14), primary cSCC (n = 66) and metastases (n = 4), to identify changes in lncRNA expression during disease progression. We developed a bioinformatics pipeline to infer lncRNA function based on co-expression patterns and generated a lncRNA signature score, which we validated in head-and-neck squamous cell carcinoma (HNSC) and pancreatic adenocarcinoma (PAAD). We performed bulk RNAseq on 15 patient-derived cell lines and integrated these data to identify tumour cell-specific lncRNAs and validated our findings in multiple other cSCC gene expression cohorts. Using in vitro knockdown approaches we investigated the functional role of LINC00941.

resultsWe found that lncRNA expression alone is sufficient to identify disease states and progression along the cSCC disease continuum. Correlation analysis revealed potentially functionally relevant lncRNAs and the processes they may regulate. We developed a 267 lncRNA signature that correlates with a progenitor-like state and predicts poor prognosis in HNSC and PAAD. Bulk RNAseq of patient-derived cell lines revealed tumour cell-specific lncRNAs, and knockdown of LINC00941 indicated that it is required for cell proliferation and colony formation in vitro.

conclusionsOur findings provide a comprehensive description of lncRNA transcriptomic changes in cSCC and demonstrate their functional relevance as biomarkers and drivers of disease progression in this and, potentially, other cancers.

Indexed as

Carcinoma, Squamous CellRNA, Long NoncodingSkin NeoplasmsAgedBiomarkers, TumorCell Line, TumorDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansKeratosis, ActinicMaleMiddle AgedSequence Analysis, RNASkinBiomarkers, TumorRNA, Long Noncoding

Identifiers

PMID40152495
PMCPMC12360040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.